Trials / Conditions / Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

17 registered clinical trials studyying Acute Myelocytic Leukemia.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood NCT06764589	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Unknown	Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML NCT06105658	Anhui Provincial Hospital	Phase 2
Unknown	Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia NCT03796390	Hebei Senlang Biotechnology Inc., Ltd.	Phase 1
Terminated	Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML NCT02255162	Massachusetts General Hospital	Phase 1
Unknown	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelo NCT02244658	Shandong University	Phase 3
Unknown	Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and NCT01809392	The First Affiliated Hospital of Soochow University	Phase 2 / Phase 3
Terminated	T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in P NCT01621477	St. Jude Children's Research Hospital	Phase 2
Completed	Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681	Novartis Pharmaceuticals	Phase 1 / Phase 2
Completed	Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematologic NCT01462578	Technische Universität Dresden	Phase 2
Completed	Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow T NCT01188798	St. Jude Children's Research Hospital	Phase 3
Completed	Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute L NCT01167166	Traws Pharma, Inc.	Phase 1 / Phase 2
Completed	Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) NCT00854646	Traws Pharma, Inc.	Phase 1
Completed	A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia NCT00559091	Jewish General Hospital	Phase 2
Completed	Experimental Bone Marrow Transplant Protocol NCT00061581	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
Unknown	Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" NCT00155844	National Taiwan University Hospital	—
Completed	Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00152139	St. Jude Children's Research Hospital	Phase 3
Completed	Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) NCT00015587	National Institute of Environmental Health Sciences (NIEHS)	—